Crossmark

Circuit-targeted modulation of anxiety symptoms in individuals with major depression: A randomized head-to-head TMS trial

Crossref DOI link: https://doi.org/10.1038/s41380-026-03535-1

Published Online: 2026-03-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Taylor, Joseph J. https://orcid.org/0000-0002-9185-0427
Li, Jing

Lin, Christopher

Jones, Emma

Frandsen, Summer https://orcid.org/0000-0003-0306-3018
Becker, Claudia R.

Drew, William

Haj-Darwish, Dania

Jabbour, Sandrine

Leach, Jessica

Palm, Stephan https://orcid.org/0009-0000-8345-5470
Sanderson, Lauren

Santos, Emanuella

Sterina, Lera

Chiulli, Nicole

Miller, John

Barantono, Sheena

Gonsalvez, Irene

Lyndon, Stanley https://orcid.org/0000-0002-2651-9754
Snider, Samuel B.

Fox, Michael D. https://orcid.org/0000-0001-8848-6399
Siddiqi, Shan H. https://orcid.org/0000-0002-0967-9289
License Information

Text and Data Mining valid from 2026-03-30

Version of Record valid from 2026-03-30
More Information

Article History

Received: 26 March 2025

Revised: 29 January 2026

Accepted: 10 March 2026

First Online: 30 March 2026

Competing interests

: SS: Owner of intellectual property involving the use of brain connectivity to target TMS, scientific consultant for Magnus Medical, investigator-initiated research funding from Neuronetics and BrainsWay, speaking fees from BrainsWay and Otsuka (for PsychU.org), shareholder in BrainsWay (publicly traded) and Magnus Medical (not publicly traded). None of these entities were involved in the present manuscript. MDF: Scientific consultant for Magnus Medical, owns independent intellectual property involving the use of functional connectivity to target TMS. This intellectual property was not used in the present manuscript. All other others deny competing of interest.

Document is current

Any future updates will be listed below